RBM7: A Drug Target / Disease Biomarker (G10179)

Target Name: RBM7

NCBI ID: G10179

RBM7

RBM7: A Drug Target / Disease Biomarker

RNA-Binding Protein 7 (RBM7) is a protein that is expressed in various tissues of the body and is known for its role in the regulation of gene expression. It is composed of 21 kDa monomers and has been shown to play a significant role in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

One of the most exciting aspects of RBM7 is its potential as a drug target. Its involvement in various cellular processes makes it an attractive target for the development of new pharmaceuticals with various therapeutic effects.

RBM7 has been shown to play a role in the regulation of cell growth and apoptosis. It has been shown to inhibit the growth of cancer cells and to promote the apoptosis of these cells. This suggests that RBM7 may be an effective target for the development of anti-cancer drugs.

In addition to its role in cell growth and apoptosis, RBM7 has also been shown to be involved in the regulation of inflammation. It has been shown to play a role in the regulation of the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6. This suggests that RBM7 may be an effective target for the development of anti-inflammatory drugs.

Another potential therapeutic application of RBM7 is its role in the regulation of metabolism. It has been shown to play a role in the regulation of glucose metabolism and to interact with the protein GLUT1. This suggests that RBM7 may be an effective target for the development of drugs that promote glucose metabolism and that target the GLUT1 protein.

In conclusion, RBM7 is a protein that has been shown to play a significant role in the regulation of various cellular processes. Its potential as a drug target makes it an attractive target for the development of new pharmaceuticals with various therapeutic effects. Further research is needed to fully understand the role of RBM7 in cellular processes and to develop effective drugs that target this protein.

Protein Name: RNA Binding Motif Protein 7

Functions: RNA-binding subunit of the trimeric nuclear exosome targeting (NEXT) complex, a complex that functions as an RNA exosome cofactor that directs a subset of non-coding short-lived RNAs for exosomal degradation (PubMed:25189701, PubMed:25578728, PubMed:25525152, PubMed:25852104, PubMed:27871484). NEXT is involved in surveillance and turnover of aberrant transcripts and non-coding RNAs (PubMed:25189701, PubMed:27871484, PubMed:25852104). Binds preferentially polyuridine sequences and associates with newly synthesized RNAs, including pre-mRNAs and short-lived exosome substrates such as promoter upstream transcripts (PROMPTs), enhancer RNAs (eRNAs), and 3'-extended products from small nuclear RNAs (snRNAs) (PubMed:25189701, PubMed:25578728, PubMed:25525152, PubMed:25852104). Participates in several biological processes including DNA damage response (DDR) and stress response (PubMed:25525152, PubMed:30824372). During stress response, activation of the p38MAPK-MK2 pathway decreases RBM7-RNA-binding and subsequently the RNA exosome degradation activities, thereby modulating the turnover of non-coding transcriptome (PubMed:25525152). Participates in DNA damage response (DDR), through its interaction with MEPCE and LARP7, the core subunits of 7SK snRNP complex, that release the positive transcription elongation factor b (P-TEFb) complex from the 7SK snRNP. In turn, activation of P-TEFb complex induces the transcription of P-TEFb-dependent DDR genes to promote cell viability (PubMed:30824372)

The "RBM7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets